KI
CRL icon

Keystone Investors’s Charles River Laboratories CRL Stock Holding History

Keystone Investors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-106,278
Closed -$22M – 75
2024
Q2 		$22M Sell
106,278
-17,339
-14% -$3.93M 1.85% 16
2024
Q1 		$33.5M Buy
+123,617
New +$29.5M 2.91% 14

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Keystone Investors's CRL Position: Q3 2024 in Review

Keystone Investors sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 106,278 shares — an estimated $22M sold.

Keystone Investors first reported a position in CRL in Q1 2024 and held it in 2 quarters. The position peaked at $33.5M in Q1 2024. 627 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Keystone Investors reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Keystone Investors sold 106,278 Charles River Laboratories shares in Q3 2024, an estimated $22M.
  • Keystone Investors first reported a position in Charles River Laboratories in Q1 2024 and held it in 2 quarters.
  • Keystone Investors's Charles River Laboratories position peaked at $33.5M in Q1 2024.
  • 627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Keystone Investors's 13F filing for Q3 2024, filed 13 Nov 2024.